A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

May 31, 2009

Study Completion Date

June 30, 2009

Conditions
Pneumonia
Interventions
DRUG

Avelox (Moxifloxacin, BAY12-8039)

IV therapy: every 24 hours, patients will be administered a 400 mg moxifloxacin infusion over 60 minutes. Oral therapy: patients will be administered a single moxifloxacin 400 mg tablet, every 24 hours

DRUG

Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin

IV therapy: every 24 hours patients will be administered a 2 g ceftriaxone infusion over 30 minutes. Following the infusion with ceftriaxone, patients will be administered a 500 mg azithromycin infusion over 180 minutes.Oral therapy: every 8 hours patients will be administered a 1000 mg amoxicillin/clavulanic acid tablet. Every 12 hours patients will be administered a 500 mg clarithromycin tablet.

Trial Locations (23)

10154

Torino

20142

Milan

20157

Milan

25123

Brescia

31029

Vittorio Veneto

33100

Udine

55100

Lucca

61034

Fossombrone

62100

Macerata

63100

Ascoli Piceno

66100

Chieti

71100

Foggia

73016

San Cesario di Lecce

82100

Benevento

84013

Pregiato Di Cava Dei Tirreni

87010

Lungro

90146

Palermo

95122

Catania

98125

Messina

00135

Roma

00168

Roma

00184

Roma

07100

Sassari

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY